"Novo Nordisk and Catalent's Race to Revolutionize Weight-Loss Drug Market"

Novo Nordisk's subsidiary, Novo Holdings, has acquired Catalent for $16.5 billion in an all-cash transaction, with plans to sell three of Catalent's facilities to its parent company. This move aims to address supply constraints and bolster manufacturing output for its popular diabetes and obesity treatments, Ozempic and Wegovy. The acquisition is expected to help Novo Nordisk meet growing demand and position the company for future blockbuster drugs, signaling a long-term strategy and strengthening investor confidence in the company's potential.